Key facts
- This page summarizes Robert Petit's Form 4 filing for OS Therapies Inc (OSTX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 30 Oct 2026, 21:00.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
On October 22, 2026, the reporting person was granted options to purchase 200,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. These options vest in 12 equal installments on each monthly anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on each applicable vesting date.
SEC remarks
Robert Petit is the Chief Medical Officer and Chief Scientific Officer of OS Therapies Incorporated.